Barclays
RCEL icon

Barclays’s Avita Medical RCEL Stock Holding History

Barclays’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12K Sell
755
-1,927
-72% -$8.31K ﹤0.01% 4828
2026
Q1 		$9.92K Sell
2,682
-16,393
-86% -$68.8K ﹤0.01% 4701
2025
Q4 		$65.8K Sell
19,075
-556
-3% -$2.22K ﹤0.01% 4684
2025
Q3 		$100K Sell
19,631
-26,928
-58% -$141K ﹤0.01% 4614
2025
Q2 		$246K Buy
46,559
+17,766
+62% +$129K ﹤0.01% 4152
2025
Q1 		$234K Sell
28,793
-12,236
-30% -$114K ﹤0.01% 3958
2024
Q4 		$525K Buy
41,029
+3,526
+9% +$41.6K ﹤0.01% 3793
2024
Q3 		$402K Buy
37,503
+28,979
+340% +$272K ﹤0.01% 3908
2024
Q2 		$67.5K Sell
8,524
-11,812
-58% -$112K ﹤0.01% 4086
2024
Q1 		$326K Sell
20,336
-14,144
-41% -$229K ﹤0.01% 3847
2023
Q4 		$473K Buy
34,480
+30,143
+695% +$346K ﹤0.01% 3909
2023
Q3 		$63.4K Sell
4,337
-671
-13% -$11.4K ﹤0.01% 3762
2023
Q2 		$85.2K Buy
+5,008
New +$73.5K ﹤0.01% 3618
2022
Q3 		– Sell
-90
Closed – – 5071
2022
Q2 		$0 Sell
90
-3,854
-98% -$23.8K ﹤0.01% 5212
2022
Q1 		$34K Buy
+3,944
New +$36.4K ﹤0.01% 4260

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's RCEL Position: Q2 2026 in Review

Barclays reduced its Avita Medical (RCEL) stake by 72% in Q2 2026, selling an estimated $8.31K and leaving 755 shares worth $3.12K. The position accounts for ﹤0.01% of the portfolio, ranked #4828.

Barclays first reported a position in RCEL in Q1 2022 and has held it in 15 quarters since. The position peaked at $525K in Q4 2024. 74 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • Barclays held 755 shares of Avita Medical worth $3.12K as of Q2 2026.
  • Barclays sold 1,927 Avita Medical shares in Q2 2026, an estimated $8.31K.
  • Avita Medical made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4828 holding.
  • Barclays first reported a position in Avita Medical in Q1 2022 and has held it in 15 quarters since.
  • Barclays's Avita Medical position peaked at $525K in Q4 2024.
  • 74 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.